CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
P/B ratio for CorMedix Inc. (CRMD)
P/B ratio as of 2023: 2.73
According to CorMedix Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.73. At the end of 2022 the company had a P/B ratio of -0.62.
P/B ratio history for CorMedix Inc. from 2009 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 2.73 |
| 2022 | -0.62 |
| 2021 | -0.70 |
| 2020 | -0.98 |
| 2019 | -0.90 |
| 2018 | -0.64 |
| 2017 | -0.18 |
| 2016 | 3.26 |
| 2015 | 1.87 |
| 2014 | 11.27 |
| 2013 | -4.26 |
| 2012 | -17.28 |
| 2011 | 2.58 |
| 2010 | 2.38 |
| 2009 | -0.17 |